FOXO4-DRI

What senescent cells are and why anyone would kill them. Cells that accumulate irreparable damage often stop dividing permanently rather than dying - a state called senescence, which evolved partly as a tumour-suppression mechanism. They persist, and they secrete a cocktail of inflammatory cytokines, proteases and growth factors known as the senescence-associated secretory phenotype. Senescent cells accumulate with age and with chemotherapy, and genetically clearing them in mice delays several features of ageing [1].

The design. The 2017 Cell paper from Peter de Keizer's group asked how senescent cells avoid apoptosis and identified FOXO4 as the pivot: in senescent cells FOXO4 binds p53 and keeps it in the nucleus, preventing the mitochondrial apoptosis that p53 would otherwise trigger. They designed a peptide that competes for that interaction. In senescent cells it causes p53 nuclear exclusion and cell-intrinsic apoptosis; normal cells, where the FOXO4-p53 interaction is not load-bearing, are spared. The peptide is retro-inverso - D-amino acids in reverse order - which resists proteolysis while preserving the binding surface, hence FOXO4-DRI [1]. A 2025 structural study mapped the target to the disordered transactivation domain of p53 [3].

The mouse results. Under conditions where it was tolerated, FOXO4-DRI neutralised doxorubicin-induced chemotoxicity, and restored fitness, fur density and renal function in both XpdTTD/TTD fast-ageing mice and naturally aged mice [1]. Later work found it targeted senescent Leydig cells and relieved age-related testosterone insufficiency in aged mice [4], improved spermatogenesis [5], killed keloid senescent fibroblasts [6] and, as a FOXO4 peptide, improved bleomycin-induced pulmonary fibrosis [7].

The counter-evidence, which is not minor. A 2023 Circulation study found senescent cells present in pulmonary arterial hypertension, and then found that eliminating senescent pulmonary endothelial cells by senolytic intervention promoted the development and progression of pulmonary hypertension [2]. Senescence is not uniformly bad; in some tissues and diseases the senescent cells are doing something necessary. Any account of senolytics that does not carry this is incomplete.

Human evidence. There is none. Not a phase 1, not a pharmacokinetic study, not a case series. Reviews continue to discuss the FOXO4-p53 axis as a pharmacological strategy - for brain ageing and cognitive decline, for instance [8] - and FOXO4 itself is being studied as a redox-sensitive regulator [9]. None of that is a trial.

In a senescent cell, p53 is present and would trigger apoptosis if it reached the mitochondria, but FOXO4 binds it and holds it in nuclear foci. FOXO4-DRI is a decoy that occupies the interaction interface. p53 is released, leaves the nucleus, and the cell undergoes intrinsic apoptosis. Because the dependence on FOXO4 is specific to the senescent state, non-senescent cells are largely unaffected [1].

The retro-inverso design is the pharmaceutical half of the idea. Reversing the sequence and using D-amino acids produces a peptide whose side chains project in roughly the same spatial arrangement as the L-peptide but which proteases cannot cleave [8]. That solves stability. It does not solve delivery, distribution or how much reaches a given tissue - none of which has been measured in any species in the literature available here.

The structural work has since shown the interaction runs through the intrinsically disordered transactivation domain of p53 [3], which is both satisfying and a caution: disordered-region interactions are promiscuous, and selectivity that holds in a dish may not hold across a whole animal.

A retro-inverso peptide: the FOXO4 sequence read backwards, built from D-amino acids. All published work uses injected routes in animals. There is no human formulation, no approved product and no published stability or delivery data [1].

There is no human safety data of any kind. The 2017 paper describes conditions under which the peptide was "well tolerated in vivo" in mice [1], which is a statement about mice.

Three concerns deserve stating plainly.

Senescence is not simply damage. It is a tumour-suppression mechanism, and it has a necessary role in wound healing and tissue remodelling. Removing senescent cells indiscriminately removes those functions too.

There is a disease where clearing them is harmful. In pulmonary arterial hypertension models, senolytic elimination of senescent pulmonary endothelial cells promoted disease development and progression [2]. This is a direct experimental result, not a theoretical worry, and nobody knows how many other contexts behave the same way.

Selectivity in vivo is assumed, not measured in humans. The mechanism's selectivity rests on senescent cells' particular dependence on FOXO4. Whether that holds across human tissues, at whatever exposure an injection actually produces, has never been tested.

A compound that instructs cells to undergo apoptosis, with no human pharmacokinetics and no dose-finding, is not in the same category as a peptide with thin efficacy evidence. The uncertainty is about what it does, not just whether it works.

No interaction studies exist. The one mechanistically relevant combination in the literature is with doxorubicin, where FOXO4-DRI neutralised chemotoxicity in mice by clearing the senescent cells the chemotherapy had created [1]. That is a plausible clinical application and it has never been tested in a person.

No interactions with other compounds on this site have been documented.